CC
SAGE

Corton Capital’s Sage Therapeutics SAGE Stock Holding History

Corton Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,025
Closed -$141K – 380
2024
Q4 		$141K Sell
26,025
-2,378
-8% -$14.5K 0.08% 311
2024
Q3 		$205K Buy
28,403
+1,562
+6% +$14.3K 0.1% 370
2024
Q2 		$291K Buy
26,841
+5,909
+28% +$75.7K 0.15% 205
2024
Q1 		$392K Sell
20,932
-2,471
-11% -$57K 0.14% 193
2023
Q4 		$507K Buy
+23,403
New +$464K 0.16% 169

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Corton Capital's SAGE Position: Q1 2025 in Review

Corton Capital sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 26,025 shares — an estimated $141K sold.

Corton Capital first reported a position in SAGE in Q4 2023 and held it in 5 quarters. The position peaked at $507K in Q4 2023. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Corton Capital reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Corton Capital sold 26,025 Sage Therapeutics shares in Q1 2025, an estimated $141K.
  • Corton Capital first reported a position in Sage Therapeutics in Q4 2023 and held it in 5 quarters.
  • Corton Capital's Sage Therapeutics position peaked at $507K in Q4 2023.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.